samedan logo

 
 
spacer
home > ebr > summer 2008 > get the message
PUBLICATIONS
European Biopharmaceutical Review

Get the Message

When considering communications and messaging for today’s smaller companies and, specifically, the biotechnology and emerging pharmaceutical industries, it is important to first recognise what sets these companies apart from their ‘big pharma’ counterparts. These distinctions are fundamental to what, in turn, drives some of the key differences in their communications.

While a handful of biotechnology companies closely resemble big and medium-size pharmaceutical companies in terms of development stage and progress in advancing drugs to market, there still remains a significant difference in the way almost all true biotech and small pharmaceutical companies approach communications and, importantly, the stories they deliver through messaging.

There are macro trends and challenges that influence how the vast majority of the healthcare industry is reaching its key stakeholders solely from a communications standpoint. However, there are distinct differences in the respective challenges these companies face that shape how their own messaging has evolved to meet the needs of these industries.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As Co-Founder of Biosector 2 and one of the healthcare industry’s most experienced Communications Consultants, Bob Chandler’s initiatives on behalf of pharmaceutical manufacturers, institutional providers, medical technology firms and the biotechnology industry are widely acknowledged as some of the most enduring and effective campaigns in recent years. For the past 25 years, Bob has consulted on a wide range of crises, corporate positioning endeavours and marketing support programmes. As the former Executive Vice-President and Co-Managing Director of Burson-Marsteller’s healthcare sector, Bob was responsible for The Biotech Group, a biotechnology division at Burson.

Gianfranco Chicco, experienced Communications Consultant and Co-Founder of Biosector 2, is the former Executive Vice President and Co-Director of the healthcare group at Burson-Marsteller. Gianfranco managed a large group of professionals and directed corporate, marketing and issues programmes for Warner-Lambert, Schering-Plough, Sandoz, Bayer and Parke-Davis. Gianfranco has served as Senior Vice President and founder of the Health and Science Communications Division of Rowland Worldwide, where he represented such companies as Sandoz Pharmaceuticals and McNeil Consumer Products.

spacer
Gianfranco Chicco
spacer
spacer
spacer
Bob Chandler
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Agilent Laboratory Achieves Green Lab Certification

SANTA CLARA, Calif. June 21, 2022 – Agilent Technologies Inc. (NYSE: A) today announced that the company’s customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification, the gold standard in laboratory sustainability best practices.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement